Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00273013
Status:
COMPLETED
Last Update Posted:
2017-10-18
First Post:
2006-01-04
Brief Title:
Study With GW274150 In Patients With Mild Asthma
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Single Centre Allergen Challenge Study of GW274150 in Mild Asthmatic Subjects
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response This will be compared with the response after treatment with a dummy placebo and a tablet treatment for asthma called Singulair montelukast Subjects in the study will receive all 3 treatments in a random order The study is double-blind so subjects will not know which treatment they are taking at any given time
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None